AstraZeneca PLC (AZN) Stock Price, Trades & News

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.23
Equity-to-Asset	0.42
Debt-to-Equity	0.72
Debt-to-EBITDA	1.69
Interest Coverage	8.18
Piotroski F-Score	9/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	3.42	Distress Grey Safe
Beneish M-Score	-2.59	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	6.4
	3-Year EBITDA Growth Rate	25
	3-Year EPS without NRI Growth Rate	32.3
	3-Year FCF Growth Rate	2.9
	3-Year Book Growth Rate	6.1
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	11.73
	Future 3-5Y Total Revenue Growth Rate Estimate	6.71

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	24.06
	9-Day RSI	33.74
	14-Day RSI	38.38
	3-1 Month Momentum %	-12.29
	6-1 Month Momentum %	-6.3
	12-1 Month Momentum %	26.56

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.91
	Quick Ratio	0.71
	Cash Ratio	0.24
	Days Inventory	213.02
	Days Sales Outstanding	80.46
	Days Payable	650.64

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.84
	Dividend Payout Ratio	0.48
	3-Year Dividend Growth Rate	0.2
	Forward Dividend Yield %	1.84
	5-Year Yield-on-Cost %	2.1
	Shareholder Yield %	2.41

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	81.68
	Operating Margin %	23.69
	Net Margin %	17.19
	EBITDA Margin %	33.48
	FCF Margin %	12.82
	OCF Margin %	23.53
	ROE %	22.66
	ROA %	9.19
	ROIC %	12.15
	3-Year ROIIC %	126.32
	ROC (Joel Greenblatt) %	105.55
	ROCE %	18.13
	Years of Profitability over Past 10-Year	10
	Moat Score	7
	Tariff Resilience Score	9

GF Value Rank

9/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	25.94
	Forward PE Ratio	16.82
	PE Ratio without NRI	25.94
	Shiller PE Ratio	49.36
	Price-to-Owner-Earnings	25.4
	PEG Ratio	1.15
	PS Ratio	4.46
	PB Ratio	5.61
	Price-to-Free-Cash-Flow	34.81
	Price-to-Operating-Cash-Flow	18.96
	EV-to-EBIT	20.08
	EV-to-Forward-EBIT	15.27
	EV-to-EBITDA	14.55
	EV-to-Forward-EBITDA	12.98
	EV-to-Revenue	4.87
	EV-to-Forward-Revenue	4.55
	EV-to-FCF	38.05
	Price-to-GF-Value	0.95
	Price-to-Projected-FCF	2.38
	Price-to-Median-PS-Value	0.96
	Price-to-Peter-Lynch-Fair-Value	1.04
	Earnings Yield (Greenblatt) %	4.98
	FCF Yield %	2.89
	Forward Rate of Return (Yacktman) %	22.64

Financials (Next Earnings Date:2026-07-27)

Annual Quarterly TTM

AZN's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with NYSE:AZN

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

AstraZeneca PLC Executives

Details

GF Value™: $179.62

AZN

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Medium warning sign with AZN. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	60,439
	EPS (TTM) ($)	6.65
	Beta	0.04
	3-Year Sharpe Ratio	0.33
	3-Year Sortino Ratio	0.53
	Volatility %	25.7
	14-Day RSI	38.38
	14-Day ATR ($)	5.758439
	20-Day SMA ($)	183.3315
	12-1 Month Momentum %	26.56
	52-Week Range ($)	138 - 212.71
	Shares Outstanding (Mil)	1,550.88

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	9
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

AstraZeneca PLC Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

AstraZeneca PLC Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings conference call for 2026	2026-11-06 13:00	In 119 days
Third quarter earnings results for 2026	2026-11-06	In 118 days
Second quarter earnings conference call for 2026	2026-07-27 11:45	In 17 days
Second quarter earnings results for 2026	2026-07-27	In 16 days
Conference, J.P. Morgan European Healthcare Forum	2026-06-18	177.89 (-0.45%)
Citi European Healthcare Conference, London	2026-06-11	178.96 (-1.09%)
Goldman Sachs Global Healthcare Conference	2026-06-08	185.95 (+1.05%)
Guidance call for 2026	2026-06-01 18:30	185.67 (-0.17%)
db Access European Champions Conference	2026-05-27	187.19 (-0.57%)
First quarter earnings conference call for 2026	2026-04-29 09:30	186.68 (-0.12%)

Show

Entries

AstraZeneca PLC Frequently Asked Questions

What is AstraZeneca PLC(AZN)'s stock price today?

The current price of AZN is $171.61. The 52 week high of AZN is $212.71 and 52 week low is $138.00.

When is next earnings date of AstraZeneca PLC(AZN)?

The next earnings date of AstraZeneca PLC(AZN) is 2026-07-27.

Does AstraZeneca PLC(AZN) pay dividends? If so, how much?

The Dividend Yield % of AstraZeneca PLC(AZN) is 1.84% (As of Today), Highest Dividend Payout Ratio of AstraZeneca PLC(AZN) was 35.15. The lowest was 0.48. And the median was 1.36. The Forward Dividend Yield % of AstraZeneca PLC(AZN) is 1.84%. For more information regarding to dividend, please check our Dividend Page.

Guru Commentaries on NYSE:AZN

Carillon Eagle Growth & Income Fund, Q2 2024 Fund Letter

Press Release

	Subject	Date
	AZN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AstraZeneca	2026-07-10
	AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN)	2026-07-09
	AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care	2026-06-24
	TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer	2026-06-12
	Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6	2026-06-02
	IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in E	2026-06-01
	IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer	2026-05-28
	DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not	2026-05-22
	AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026	2026-05-22
	BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension	2026-05-18

10/Page

Articles on AstraZeneca PLC

AZN

AstraZeneca's (AZN) Vaccine Influence Under Scrutiny Amid New Administration Nomination

22 hours ago

AZN

AZN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AstraZeneca

1 day ago

AZN

AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN)

1 day ago

AZN

AstraZeneca PLC (AZN) Shares Fall 5.7% -- What GF Score of 82 Tells Investors

1 day ago

AZN

AstraZeneca (AZN) Wins Patent Dispute Over Tagrisso

1 day ago

Headlines

Jul 09, 2026

At a glance: stocks gapping down premarket

Seeking Alpha • 7:12am

Biggest stock movers Thursday: AZN, AP, and more

Seeking Alpha • 3:33am

AstraZeneca tumbles as heart drug trial misses main efficacy goal

Seeking Alpha • 2:50am

Jul 08, 2026

Sino Biopharma receives Chinese rights to two GSK respiratory drugs

Seeking Alpha • 9:26am

AstraZeneca to pay $200M upfront for Sino Biopharmaceutical’s COPD drug license deal

Seeking Alpha • 11:38pm

Jul 05, 2026

Top global stories this week; markets rally on rate-cut optimism

Seeking Alpha • 12:45pm

Jul 02, 2026

AstraZeneca inks kidney therapy deal worth up to $1.77B with China’s CSPC

Seeking Alpha • 7:02am

AstraZeneca, Abbisko partner on lung cancer combination therapy trial

Seeking Alpha • 11:33pm

Jun 15, 2026

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod

Benzinga • 11:51am

Jun 12, 2026

AstraZeneca gets FDA label expansion for Truqap in prostate cancer

Seeking Alpha • 1:33pm

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.